BMYBristol-Myers Squibb Company
# 14 · $61.48 (-2.41%) · $125.59B · Healthcare
52-week range
High-severity risk signals
The scoring engine flagged these high-severity signals. They are warnings to investigate and are not part of the score.
- Altman Z in distress zone
Market data
- P/E
- 13.54
- 1M
- +1.00%
- 1Y
- +46.51%
- Yield
- 4.10%
- RSI
- 58.16
- MACD
- +0.76%
Breakdown
Why
- P/E of 13.5
- free cash flow yield 9.1%
- earnings growth of -6.2% a year over 2 years (+178.8% in the latest year alone, inflated by an unusually low prior year)
- ROE of 41.6%
- profit margin of 18.9%
- margin and ROA expanding YoY
- 12-1 momentum return of 45.1%
- trading 4.7% above 200d SMA
- MACD histogram positive
- EPS vs. estimates: +12.8% on average
Rationale is generated by the scoring engine (English).
Piotroski F-Score
8
8 / 9 checks passed
- roa positive
- ocf positive
- roa improving
- accruals
- leverage decreasing
- liquidity improving
- no dilution
- margin improving
- turnover improving
Altman Z-Score
Risk signals
- Altman Z in distress zoneHigh
Z-Score 1.44 (< 1.81) — financial distress risk per the Altman model
- High leverageMedium
debt/equity 202% (alert threshold 200%)
- Share dilutionInfo
shares outstanding higher than the previous fiscal year
- Geographic revenue concentrationInfo
69% of revenue from United States
- Product revenue concentrationInfo
97% of revenue from Net Product Sales
Company research
Business Overview Bristol Myers Squibb (BMS) is a global biopharmaceutical company focused on discovering, developing, and commercializing prescription medicines in areas including oncology, hematology, immunology, cardiovascular, and neuroscience, generating revenue primarily from branded drug sales to wholesalers, hospitals, and specialty channels. Market Position BMS is a major large-cap pharma competitor with a strong position in oncology and hematology, supported by a broad commercial portfolio and a pipeline spanning multiple therapeutic modalities; competition is driven by clinical differentiation, label breadth, and lifecycle management versus other large innovative biopharmas. Key Segments BMS operates as a single, integrated biopharmaceutical segment, with internal reporting typically organized around therapeutic franchises rather than separately disclosed operating segments.
AI-generated summary based on third-party data; it may contain errors. Not investment advice or a recommendation to invest.
Period: 2021-12-31 → 2025-12-31